Video

Dr. Nixon on the Role of MSI in Cancer

Andrew B. Nixon, PhD, ​MBA, discusses the role of microsatellite instability in cancer.

Andrew B. Nixon, PhD, ​MBA, director, Phase 1 Biomarker Laboratory, associate professor of medicine, Duke University School of Medicine, discusses the role of microsatellite instability (MSI) in cancer.

MSI describes an accumulation of mutations in the telomere region of the chromosome, says Nixon. These mutations represent insertions or deletions, also known as tandem repeats.

Tandem repeats are measurable and occur in ​the DNA when nucleotide pattern repetitions are near one another​, Nixon says.

Notably, a large number of mutations or alterations is in this region of the chromosome, the tumor is deemed microsatellite ​instable, ​says Nixon. This instability is due to a functional loss of DNA mismatch repair (MMR) enzymes.

Although these consist of many proteins, ​MLH1, MSH2, MSH6, and PMS2 are looked at most closely. ​Moreover, an alteration in these MMR proteins results in an MSI phenotype, Nixon concludes. 

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine